Recombinant Activated Factor VII (rFVIIa) as a Hemostatic Agent in Liver Disease: A Break from Convention in Need of Controlled Trials

Hepatology

Volumn 39, Issue 3, 2004, Pages 592-598

  Caldwell, Stephen H ^a,b   Chang, Charissa ^a   Macik, B Gail ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; VITAMIN K GROUP;

BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION REACTION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DYSFIBRINOGENEMIA; HUMAN; KIDNEY FAILURE; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTE FUNCTION;

BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; FACTOR VII; FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HUMANS; LIVER DISEASES; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 1542619698     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20123     Document Type: Review

References (57)

1. Sue M, Caldwell SH, Dickson RC, Macalingdong C, Rourk RM, et al. Variation between centres in technique and guidelines for liver biopsy. Liver 1996;16:267-270.
2. Mayoral W, Lewis JH. Percutaneous liver biopsy. What is the current approach? Results of a questionnaire survey. Dig Dis Sci 2001;46:118-127.
3. Dzik S. The use of blood components prior to invasive procedures: a critical appraisal. In: Mintz PD, editor. Transfusion Therapy: Clinical Principles and Practice. Bethesda, MD: AABB Press, 1999:153-156.
4. Hedner U. Recombinant coagulation factor VIIa: from concept to clinical application in hemophilia treatment in 2000. Semin Thromb Hemost 2000;26:363-366.
5. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a "prima ballerina." Thromb Haemost 1995;74:7-17.
6. Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr Med Chem 2003;10:797-811.
7. Tholstrup T, Miller GJ, Bysted A, Sandstrom B. Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men. Am J Clin Nutr 2003;77:1125-1132.
8. Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989;73:359-365.
9. Hendriks HG, Meijer K, de Wolf J, Porte RJ, Klompmaker IJ, Lip H, Slooff MJ, et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002;13:309-313.
10. Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. HEPATOLOGY 2002;35:616-621.
11. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-648.
12. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, Bech R, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930-1937.
13. Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001;114:114-120.
14. O'Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.
15. Bernuau J, Samuel D, Durand F, Saliba F, Bourliere M, Adam R, Gugenheim J, et al. Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V below 50% of normal: a prospective study [abstract]. HEPATOLOGY 1991;14:49A.
16. Riordan SM, Williams R. Use and validation of selection criteria for liver transplantation in acute liver failure. Liver Transpl 2000;6:170-173.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
18. Infante-Rivard C, Esnaola S, Villeneuve J-P. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. HEPATOLOGY 1987;7:660-664.
19. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunt. HEPATOLOGY 2000;33:464-470.
20. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 1994;78:545-554.
21. Peck-Radosavljevic MP, Zacherl J, Meng YG, Pidlich J, Lipinski E, Langle F, Steininger R, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997;27:127-131.
22. Samuel H, Nardi M, Karpatkin M, Hart D, Belmont M, Karpatkin S. Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements. Br J Haematol 1999;105:1086-1091.
23. Hersch S, Kunelis T, Francis RV. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987;69:1315-1319.
24. Green G, Thomson JM, Dymock IW, Poller L. Abnormal fibrin polymerization in liver disease. Br J Haematol 1976;34:427-439.
25. Wanless IR. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. HEPATOLOGY 1995;21:1238-1247.
26. Bakker C, Knot E, Stibbe J, Wilson J. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol 1992;15:330-335.
27. Zachee P, Vermylen J, Boogaerts MA. Hematologic aspects of end-stage renal failure. Ann Hematol 1994;69:33-40.
28. Rubin MH, Weston MJ, Langley MH, White Y, Williams R. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 1979;24:197-202.
29. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981;26:388-393.
30. Boks AL, Brommer EJ, Schalm SW, Van Vliet. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. HEPATOLOGY 1986;6:79-86.
31. Kovacs MJ, Wong A, MacKinnon K, Weir K, Keeney M, Boyle E, Cruickshank M. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994;71:727-730.
32. Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? HEPATOLOGY 1996;24:1392-1394.
33. Mallett SV, Cox DJ. Thromboelastography. Br J Anaesth 1992;69:307-313.
34. Grant A, Neuburger J. Guidelines for the use of liver biopsy in clinical practice. Gut 1999;45(Suppl IV):IV1-IV11.
35. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med 1993;118:151-153.
36. Caldwell SH. Controlling pain in liver biopsy. Am J Gastroenterol 2001;96:1327-1329.
37. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002;123:118-126.
38. Shami V, Caldwell S, Hespenheide E, Arseneau K, Bickston S, Macik G. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003;9:138-143.
39. Chuansumrit A, Treepongkaruna S, Phuaradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 2001;85:748-749.
40. Quan DJ, Bass NM, Hirose R. The effect of recombinant factor VIIa and fresh frozen plasma on the INR in patients with acute and chronic liver failure [abstract]. HEPATOLOGY 2003;38:550A.
41. O'Grady, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of fulminant hepatic failure. Semin Liver Dis 1986;6:159-163.
42. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986;90:1232-1240.
43. Castaneda B, Morales J, Lionetti R, Moitinho E, Andreu V, Perez-Del-Pulgar S, Pizcueta P, et al. Effects of blood volume restitution following portal hypertensive-bleeding in anesthetized cirrhotic rats. HEPATOLOGY 2001;33:821-825.
44. Thabut D, De Franchis R, Bendtsen F, D'Amico G, Albillos A, Abraldes J, Fabricius S, et al. Efficacy of activated recombinant factor VII in cirrhotic patients with upper GI bleeding: a randomized, placebo-controlled, double-blind multicenter trial. Gastroenterology 2003;124:A697.
45. Ejlersen E, Melsen T, Ingerslev J, Adreasen R, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001;10:1081-1085.
46. Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, Gomez-Parra M, Arias F, Guerrero-Aznar M, Sendon-Perez A, et al. Recombinant-activated Factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clinical Gastroenterology and Hepatology 2004;2:78-84.
47. Runyon BA. Management of adult patients with ascites caused by cirrhosis. HEPATOLOGY 1998;27:264-272.
48. DeLoughery TG, Liebler JM, Simonds V, Goodnight SH. Invasive line placement in critically ill patients: do hemostatic defects matter? Transfusion 1996;36:827-831.
49. Goldfarb G, Lebrec D. Percutaneous cannulation of the internal jugular vein in patients with coagulopathies: an experience based on 1,000 attempts. Anesthesiology 1982;56:321-323.
50. Smith OP, Hann IM. RVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Br J Haematol 1996;92:1002-1004.
51. Berthier AM, Guillygomarc'h A, Messner M, Pommereuil M, Bader G, De Mello G. Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients. Vox Sang 2002;82:119-121.
52. Anantharaju A, Mehta K, Mindikoglu AL, van Thiel DH. Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci 2003;48:1414-1424.
53. Steib A, Freys G, Lehmann C, Meyer C, Mahoudeau G. Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth 2001;48:1075-1079.
54. Kalicinski P, Kaminski A, Drewniak T, Szymczak M, Markiewicz M, Lukasiewicz H. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999;31:378-379.
55. Hendriks HGD, Meijer K, de Wolf JThM, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJM, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation 2001;71:402-405.
56. Carr ME Jr, Kuhn JG, Marin EJ, Tidwell AR, Hagan MK. Psuedoprolongation of the prothrombin time during treatment for bleeding with a spontaneous factor VIII inhibitor. Int J Hematol 2003;77:308-309.
57. Shapiro SS. Treating thrombosis in the 21st century. N Engl J Med 2003;349:1762-1764.